Biogenum Announces Favorable Safety Profile for Tau NonTangles™ in a Phase 1/2 Clinical Trial in Patients with Alzheimer
Tau NonTangles™ - small molecule for Alzheimer’s disease treatment is associated with clinical signs consistent with improvements in motor symptoms. BUSAN, YEONGNAM, SOUTH KOREA, December 8, 2019 /EINPresswire.com/ -- Biogenum (ISIN: KR7013369996), a …